XORTX Therapeutics
XRTX
6 hedge funds and large institutions have $124K invested in XORTX Therapeutics in 2025 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 2 closing their positions.
88% more capital inflows, than outflows
Capital inflows: $152K | Capital outflows: $81.1K
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
20% more funds holding
Funds holding: 5 → 6 (+1)
0.65% more ownership
Funds ownership: 2.67% → 3.31% (+0.65%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DRW Securities
Chicago,
Illinois
|
+$128K |
| 2 |
Baader Bank Aktiengesellschaft
Unterschleissheim,
Germany
|
+$12.4K |
| 3 |
Two Sigma Securities
New York
|
+$8.35K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$2.47K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$773 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$69.9K |
| 2 |
XTX Topco
George Town,
Cayman Islands
|
-$11.2K |
| 3 |
SBI Securities
Tokyo,
Japan
|
-$1 |
XRTX Hedge Fund Activity: Q4 2025 in Review
6 of the 8,303 institutional investors tracked by Wall St. Rank reported a position in XORTX Therapeutics (XRTX) for Q4 2025, worth a combined $124K — up 52% from $81.5K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new XRTX positions and 2 closed out — a net gain of 1 holder — while 2 added to existing stakes and 0 trimmed.
The largest buyer was DRW Securities, opening a new position worth an estimated $128K. The largest seller was Citadel Advisors, exiting entirely with an estimated $69.9K sold.
- 6 institutional investors held XORTX Therapeutics (XRTX) as of Q4 2025, up from 5 in Q3 2025.
- Funds reported $124K of XORTX Therapeutics stock for Q4 2025, up 52% quarter-over-quarter.
- 3 funds opened new XORTX Therapeutics positions in Q4 2025 and 2 closed out, a net change of +1 holder.
- The largest XORTX Therapeutics buyer in Q4 2025 was DRW Securities, an estimated $128K added.
- The largest XORTX Therapeutics seller in Q4 2025 was Citadel Advisors, an estimated $69.9K sold.
Based on aggregated 13F filings for Q4 2025.